Skip Navigation LinksHome > Current Issue > Addressing the Challenges of Serogroup B Meningococcal Disea...
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0000000000000197
NFID Clinical Update

Addressing the Challenges of Serogroup B Meningococcal Disease Outbreaks on Campuses

Schaffner, William MD*; Baker, Carol J. MD†‡; Bozof, Lynn§; Engel, Jeffrey MD; Offit, Paul A. MD¶#; Turner, James C. MD**

Free Access
Continued Medical Education
Article Outline
Collapse Box

Author Information

From *Department of Health Policy and Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN; †Baylor College of Medicine, and ‡Center for Vaccine Awareness & Research, Texas Children’s Hospital, Houston, TX; §National Meningitis Association; and ║Council of State and Territorial Epidemiologists, Atlanta, GA; ¶Division of Infectious Diseases, and Vaccine Education Center, Children’s Hospital of Philadelphia; and #University of Pennsylvania School of Medicine, Philadelphia, PA; and **National Social Norms Institute and University of Virginia School of Medicine, Charlottesville, VA.

Correspondence to: Ellyn Terry, Education & Public Outreach, National Foundation for Infectious Diseases (NFID), 7201 Wisconsin Ave, Suite 750, Bethesda, MD 20814. E-mail: ETerry@nfid.org.

Reprinted with permission from the National Foundation for Infectious Diseases. Copyright © 2014 National Foundation for Infectious Diseases.

TARGET AUDIENCE

Physicians and other healthcare professionals interested in the causes, prevention, and treatment of serious infections due to meningococcal disease.

EDUCATIONAL OBJECTIVES

Following the education activity, participants will be able to explain the changing epidemiology of meningococcal disease in the United States; evaluate the effectiveness of the use of meningococcal B vaccine used in the setting of outbreaks of disease among students at 2 universities; describe behavioral factors that are associated with increased risk of meningococcal disease in university student populations; and appraise an array of challenges and recommendations dealing with preventing and responding to meningococcal group B outbreaks on university campuses.

PARTICIPATION IN THE LEARNING PROCESS

Credit is based on the approximate time it should take to read this publication and complete the assessment and evaluation. A minimum assessment score of 80% is required. Publication date is September 1, 2014. Requests for credit or contact hours must be postmarked no later than March 1, 2015, after which this material is no longer certified for credit.

CONTINUING MEDICAL EDUCATION

The National Foundation for Infectious Diseases (NFID) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The NFID designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE

The NFID must ensure balance, independence, objectivity, and scientific rigor in its educational activities. All individuals with control over content are required to disclose any relevant financial interest or other relationship with manufacturer(s) of any product or service discussed in an educational presentation and/or with the commercial supporters of this activity. Disclosure information is reviewed in advance to manage and resolve any conflict of interest, real or apparent, that may affect the balance and scientific integrity of an educational activity.

Carol J. Baker (faculty) served as an advisor or consultant for Novartis Vaccines and Pfizer Inc.

Marla Dalton (NFID staff, content reviewer) served as an advisor or consultant for Pfizer Inc and owns stock, stock options, or bonds from Merck & Co, Inc. Susan J. Rehm (NFID medical director, content reviewer) served as an advisor or consultant for Cubist, Merck & Co, Inc, and Pfizer Inc, and served as a speaker or a member of a speaker’s bureau for Genentech and Pfizer Inc. William Schaffner (faculty) served as an advisor or consultant for Merck & Co, Inc, Pfizer Inc, and Dynavax; and served as a speaker for Sanofi Pasteur. Ellyn Terry (NFID staff, content reviewer) served as an advisor or consultant for MedImmune and has received financial or material support from Sigma-Tau Pharmaceuticals, Inc. All other authors, planners, and content reviewers have no funding or conflicts of interest to disclose.

CME INSTRUCTIONS

To receive credit after reading the publication, complete and return the self-assessment examination, evaluation, and your contact information, via fax to 301-907-0878 or by mail to NFID CME Office, 7201 Wisconsin Ave, Suite 750, Bethesda, MD 20814.

No fee is required. Please allow 2 to 4 weeks for processing. Inquiries may be directed to 301-656-0003 x16 or cme@nfid.org.

Editorial Note: This publication is based on a virtual expert roundtable discussion held April 8, 2014, titled “Addressing the Challenges of Serogroup B Meningococcal Disease Outbreaks on Campuses.”

Collapse Box

Abstract

Recent outbreaks of serogroup B invasive meningococcal disease on US college campuses have heightened awareness about the gap in available vaccines to protect against this serious and sometimes fatal infection. Federal agencies, college health authorities, public health officials, and consumer advocates are in a heightened state of awareness about the challenges of facing this unpredictable disease and the need for an effective and timely public health response when outbreaks occur. Challenges in responding to the recent outbreaks provided a compelling reason for the National Foundation for Infectious Diseases to assemble a panel of stakeholders/subject matter experts to examine the public health response to the recent outbreaks and strategies for appropriate and streamlined public health responses to future outbreaks.

Two recent but very different outbreaks at Princeton University and the University of California, Santa Barbara (UCSB), are challenging how public health officials define and respond to meningococcal disease outbreaks. While the outbreak at UCSB followed a more “typical” outbreak pattern, with 4 cases occurring in rapid succession over 2 weeks, the Princeton outbreak included 9 cases over a longer period (about 1 year) with variable intervals between cases. Each outbreak was confined to students, with no cases reported in faculty, staff, or the surrounding community population. Also, the 2 outbreak pathogens were genetically unrelated.

As of May 2014, public health officials could not say with certainty whether either outbreak was over. Both outbreaks, along with 3 other college campus outbreaks in the last 5 years in which the Centers for Disease Control and Prevention (CDC) was consulted, were caused by meningococcal serogroup B bacteria. This serogroup is not included in the currently (May 2014) licensed meningococcal vaccines administered to US adolescents or to individuals of other ages with certain risk factors that make them susceptible to invasive meningococcal disease.1

Managing any invasive meningococcal disease outbreak is demanding, but the lack of a licensed vaccine against serogroup B made public health decisions even more challenging in these recent circumstances.2 Lack of a vaccine makes it harder to create a targeted outbreak containment strategy and makes attempts to develop a population-based prevention strategy more difficult.

Although most invasive meningococcal disease cases are isolated and do not signal an impending outbreak,3 even 1 case on campus can cause serious medical and social stress, including public concern about transmission into the general community. The public is highly attuned to the severity of invasive meningococcal disease, mandating a response from college and local public health officials. At a minimum, college or public health officials will identify close contacts for postexposure antibiotic prophylaxis. Beyond that, as the 2 recent outbreaks demonstrate, the next steps are less clear.

When college outbreaks do occur, they often place a large burden on campus resources. Outbreak management requires coordination and cooperation among many groups, including campus health authorities, local and state public health departments, college staff, faculty, students, and parents, as well as significant financial and personnel resources. The CDC will often be consulted, as was the case in both the Princeton and UCSB outbreaks.

The authors gratefully acknowledge the following individuals who presented data during the April 8, 2014, roundtable that informed the ideas and recommendations presented: Amanda Cohn, MD (CDC); Mary Ferris, MD (UCSB); Peter Johnsen, MD (Princeton University); Jessica MacNeil, MPH (CDC); and Wellington Sun, MD (FDA).

This activity is supported by an unrestricted educational grant from Novartis Vaccines and Diagnostics, Inc. National Foundation for Infectious Diseases (NFID) policies restrict funders from controlling program content.

Back to Top | Article Outline
US Adolescents Are Well Vaccinated Against Meningococci, But Not Protected Against Serogroup B

The meningococcal vaccines currently approved for use in the United States protect against serogroups A, C, W-135, and Y.1 Because serogroup B bacteria differ structurally, a serogroup B vaccine has been more difficult to produce.4,5 The current meningococcal vaccines are recommended for routine vaccination of adolescents at 11 to 12 years of age with a booster dose at 16 years of age and roughly 3 quarters of US teens are currently immunized.1,6

Whereas there is no licensed US vaccine to protect against serogroup B, there is a serogroup B vaccine approved for use in Europe, Canada, and Australia.7 This vaccine, manufactured by Novartis Vaccines, was used under an investigational new drug (IND) agreement between the US Food and Drug Administration (FDA) and CDC to help control the outbreaks at Princeton and UCSB.

The Novartis vaccine and another serogroup B vaccine in development by Pfizer have recently been granted “breakthrough therapy” status by the FDA.8,9 Both vaccines will be reviewed on a new accelerated schedule to help meet US public health needs.10

Back to Top | Article Outline
Invasive Meningococcal Disease Is Fast Moving and Deadly

Invasive meningococcal disease is characterized by rapid progression (typically hours but occasionally several days) from symptom onset to severe outcomes, even when it is diagnosed and treated quickly.11–13 Although the most common clinical manifestations of invasive meningococcal disease are severe—meningitis with or without bacteremia, and pneumonia in adults—its earliest symptoms may be nonspecific and “flu like.”11,14 These can quickly progress to more severe and specific symptoms including stiff neck, nausea, vomiting, confusion, and a telltale reddish pink/purplish rash (purpura fulminans), usually on the lower extremities or lower arms and hands.

Mortality from invasive meningococcal disease is 10% to 15% (death can occur within hours or days) and among survivors is associated with an 11% to 19% risk of serious long-term sequelae, such as hearing loss, skin scarring, brain damage, kidney failure, and limb amputations.1,11–13 The disease occurs mostly in previously healthy individuals.

College campuses are a focus of meningococcal disease prevention efforts because of the increased incidence of the disease during adolescence and young adulthood.15,16 This increased risk is likely due to enhanced person-to-person transmission from crowded living conditions and social behaviors common among college students including going to bars and parties, alcohol consumption, more than 1 kissing partner, and smoking.2,17,18 Meningococcal bacteria are not spread by casual contact or by simply breathing the air where a person with meningococcal disease has been.

Back to Top | Article Outline
Epidemiology and Burden of Serogroup B Meningococcal Disease

Invasive meningococcal serogroup B disease is similar to serogroups A, C, W-135, and Y in clinical presentation, morbidity, and mortality. The highest incidence of serogroup B disease is in infants younger than 1 year, but a second peak is seen in adolescents.14,19 In recent years, serogroup B has overtaken serogroups C and Y as the most common cause of disease in adolescents. This may be, in part, a result of high vaccination coverage against serogroups C and Y.

Meningococcal disease incidence has been declining in the United States since the late 1990s. The decline began before high vaccine coverage was achieved and has been seen in all serogroups, including serogroup B.6,20

In higher incidence years (1997–1999), there were 780 meningococcal disease cases in individuals aged 11 to 24 years, with 142 of them caused by serogroup B. In recent, lower incidence years (2010–2012), there were 106 cases in this age group with 29 caused by serogroup B.20

But it is important to note that meningococcal disease is characterized by its volatile and irregular epidemiology. It has been described as having a cyclic nature with peaks and troughs, and Cohn et al14 discuss the “historical precedence for major shifts in meningococcal disease patterns.” These shifts may include changes in incidence, changes in the proportion of cases caused by each serogroup, peaks emerging in different age groups, and regional changes in epidemiology.14,21,22

Back to Top | Article Outline
The Challenge of Creating a Serogroup B Vaccine

Currently licensed meningococcal vaccines use a fragment of the polysaccharide outer coating of meningococcal bacteria to trigger the body’s immune response.4 Although this has worked well for other serogroups, the outer coating (capsule) on serogroup B bacteria does not induce an immune response because it too closely resembles other human cells.4,5 Scientists have now isolated protein fragments on the outer surface of serogroup B bacteria that induce immunity and are present on a large enough percentage of B strains to make the vaccine effective for widespread use. These vaccines appear to be effective against many, but perhaps not all, serogroup B strains.

Back to Top | Article Outline
Princeton University: Yearlong Outbreak With Atypical Clinical Presentations

In March 2013, a Princeton University student was diagnosed with serogroup B invasive meningococcal disease while on break with her family in another state (Fig. 1). A few weeks later, a prospective student who had visited the campus was diagnosed with the disease, but the cases were not immediately connected. The university instituted postexposure antibiotic prophylaxis for close contacts of both cases and asked medical staff to be alert to other students presenting with meningococcal disease symptoms.

FIGURE 1
FIGURE 1
Image Tools

Within a few weeks, another student was diagnosed with serogroup B invasive meningococcal disease. A look back at the second case revealed that it, too, was caused by serogroup B. The New Jersey Department of Health (NJDOH) declared the 3 cases a cluster, and Princeton began a widespread hygiene campaign to educate students about ways to reduce transmission. Messages were delivered via posters in dormitories, table tent cards in the dining halls, brochure distributions, meetings, e-mails, and a dedicated Web site.

A fourth case followed quickly, and by this time, genetic testing of strains confirmed that all 4 cases were identical, and the NJDOH declared an outbreak. While the educational campaign and targeted prophylaxis continued, the university prepared for the end of the school year, which raised major concern because some 20,000 people would be crowding the campus for reunion and commencement activities, increasing fears about further transmission. On the other hand, there was also hope that the summer recess to follow would halt transmission completely and stop the outbreak.

The semester concluded with no new cases, but in late June another case occurred, this time in a Princeton student traveling abroad in Greece with a group of about 15 other Princeton students. By early July 2013, Princeton, CDC, and NJDOH officials were discussing the possibility of a vaccination campaign, but because these cases were all caused by serogroup B, they needed FDA permission to use an investigational vaccine. Initial steps toward a vaccination program began in August 2013.

Princeton University continued its hygiene campaign in the fall and even engaged students to help develop new messages that would resonate with their peers. But 3 more cases occurred on campus in the fall, bringing the total to 8. With each new case came prophylaxis of contacts and increased stress on campus. With the initial steps toward getting an IND already in place by the CDC, Princeton was able to move forward quickly with vaccination plans.

The IND was approved just before the eighth case was diagnosed in late November, and the first vaccine clinic was scheduled for early December 2013. Once Princeton officials were convinced that widespread immunization with the investigational serogroup B vaccine was the best course, they had to develop and implement a communication plan quickly and set up the first vaccination clinics, which they modeled on their influenza vaccination clinics.

Princeton delivered the 2-dose vaccine series to 90% of its students. Although it was an enormous undertaking with extensive educational efforts, campus officials recognized that the high uptake rates were influenced by the perceived risk among students.

The last case had only been reported a few weeks before the first vaccine clinic, so student (and parent) fear and motivation were high. In addition, shortly before the first clinic, news of a student at UCSB suffering bilateral foot amputations from meningococcemia was reported. Finally, the vaccine clinic followed the Thanksgiving break, during which campus officials believe parents urged their children to be vaccinated.

Unfortunately, the outbreak associated with Princeton still may not be over. In March 2014, a Drexel University student died of invasive meningococcal disease after close contact with a group of Princeton students who traveled to Drexel for a social event. Molecular typing confirmed the case was caused by the identical B strain at Princeton. Princeton has since decided to offer the serogroup B vaccine to all incoming freshmen in September 2014 in an effort to prevent additional cases.

Back to Top | Article Outline
A Typical Clinical Presentations Worry Princeton Medical Staff

One of the biggest concerns for the Princeton medical staff was making a rapid diagnosis so students could be treated quickly. Whereas some cases presented with clear clinical markers for invasive meningococcal disease (headache, high temperature, stiff neck, petechial rash), others did not.

One student reported a high fever the night before (103°F), but when she presented the next day at the infirmary, she had a low-grade fever (<100°F), was alert and joking, and had no other symptoms consistent with an invasive meningococcal disease diagnosis. Nonetheless, physicians checked her white blood cell count (elevated at approximately 27.0 k/uL), took blood cultures, and sent her to the hospital. The cultures later confirmed meningococcemia, and the patient continued to worsen in the hospital.

Another student presented in the infirmary with exudative tonsillitis. He had a fever of 103°F and a positive rapid strep test. He was diagnosed with group A streptococcal tonsillitis and kept overnight because of the fever. But in the middle of the night, he developed the telltale petechial rash of meningococcemia. He was promptly admitted to a local hospital, where he developed multiorgan failure just a few hours later.

Immediate diagnosis was hindered in these cases by the lack of readily recognizable clinical markers. Milder and atypical presentations left the Princeton medical staff concerned and uneasy about making rapid, accurate diagnoses.

Back to Top | Article Outline
University of California, Santa Barbara: 4 Cases in 2 Weeks

There were 4 meningococcal serogroup B cases on the UCSB campus in November 2013. Epidemiologic investigation later linked these cases to another that occurred 7 months earlier. The 5 students appeared to have little in common. Four were male; 1 was a senior, 2 were freshmen, and 2 were sophomores. They lived at 5 different locations and in very different living environments including a 1300-bed high-rise dormitory, a private apartment, and a sorority house (3 were involved in Greek life).

Four had social interactions consistent with known risk factors for contracting meningococcal disease, but in the fifth case, only a remote connection could be identified—a roommate who was on a sports team with another case. The 4 cases in November all occurred shortly after a widely attended Halloween event in a densely populated community near campus. Students report that it is not uncommon for partygoers to share cups, glasses, and smoking materials and to participate in kissing games.

Not only does UCSB have a large student population (19,000 undergraduates), but it also sits just 5 miles away from a similarly sized but nonresidential community college. It is not unusual for students from both schools to socialize together on the campuses and in and around the neighboring town.

The Santa Barbara Public Health Department was very involved in helping UCSB investigate the cases and define the target population for postexposure antibiotic prophylaxis. But there were challenges. One of the students presented in septic shock, making it difficult to get a complete history. Investigators identified close contacts of this case on the lacrosse team for prophylaxis but learned later of his involvement with several other sports teams only when those teammates came to the infirmary asking to also be treated as close contacts.

Officials from UCSB, the Santa Barbara Public Health Department, and CDC debated how broadly to use postexposure prophylaxis. In the end, the university administered nearly 1200 prophylactic doses of ciprofloxacin. This broad-based approach was agreed to, in part, in response to unease on the campus as well as the difficulty in defining close contacts rigorously. In addition to prophylaxis, the university began a large educational campaign on ways to reduce transmission. This included directives to avoid risky social behaviors. University officials cannot say definitively whether the prevention messages had an impact on student behavior; anecdotally, students reported that the campaign influenced their choices.

Within 10 days of the fourth case, discussions began about seeking an IND for use of the unlicensed serogroup B vaccine to help control the outbreak. The discussions included university officials, the CDC, and county and state public health officials. The decision was made to pursue an IND, and CDC prepared the application with their epidemiologic analysis, including definition of the target population for vaccination as the entire undergraduate student body. Because the local public health department did not have the capacity to deliver vaccines to such a large target population, the responsibility fell solely on UCSB.

It took 3 months to get the necessary approvals from CDC and FDA and set up the first vaccine clinic. During that time, campus officials worked closely with CDC to resolve issues related to the IND application process with FDA, as well as required contracts and procurement. They faced logistical and practical challenges. The university had to purchase and install 5 commercial refrigerators to maintain the vaccine cold chain, and they transformed a hockey rink into a vaccine clinic, which required running new electrical lines, installing computers and Internet service, bringing in medical equipment and privacy screens, and so on. They supplemented UCSB staff with outside nurses and administrative personnel to staff the clinic.

University officials and public health experts believe the 3-month gap between the last case and the vaccination clinic diminished the sense of urgency for vaccination among students. Still they achieved a first-dose coverage rate of 51%, with rates of 60% for dormitory residents and Greek life members. Thirty-seven percent of undergraduates received the full 2-dose series, with higher completion rates among freshmen (50%) and sophomores (45%).

Back to Top | Article Outline
Lack of Clear Clinical Markers in UCSB Meningococcal Cases

Local doctors have become apprehensive about missing or delaying a meningococcal diagnosis. This has resulted in an increase in emergency department visits and blood cultures not just on campus, but also across the local area.

Whereas 1 case was diagnosed quickly, 2 of the invasive meningococcal disease cases at UCSB were not. One student was sent home from the emergency room, and another who had rash and fever was diagnosed with chickenpox. The meningococcal diagnoses were made for these 2 students when blood cultures turned positive 1 and 2 days later, respectively.

Back to Top | Article Outline
Challenges and Recommendations
Back to Top | Article Outline
Licensure of Meningococcal Serogroup B Vaccines Will Have the Single Greatest Impact on Improving Responses to Future Outbreaks

Once the serogroup B vaccines are licensed, the CDC Advisory Committee on Immunization Practices will provide recommendations for their use in endemic and outbreak circumstances.

However, because of the extreme nature and epidemiology of meningococcal disease, the changing epidemiology, and the experience of recent outbreaks, the panel did advance some thoughts about the potential ways serogroup B meningococcal vaccines might be used.

The logic of adding serogroup B prevention to current routine immunization strategies was discussed. If invasive meningococcal disease is severe enough to warrant routine immunization with one of the available vaccines, and the current high vaccine coverage rates would argue that health care professionals (HCPs) and parents believe it is, then we must give equal weight to preventing disease caused by all serogroups, not just those in the current quadrivalent vaccines. The panel recognized the public health challenges of adding vaccine doses for adolescents. The panel concluded that a CDC recommendation that goes beyond outbreak control will provide a possible solution, vaccination. It may also facilitate insurance coverage for vaccinations.

Back to Top | Article Outline
Increased Efforts Needed to Educate and Raise Awareness Among HCPs About Invasive Meningococcal Disease Presentation

There was a spectrum of clinical presentations in the 2 recent college outbreaks. Clinicians who were more alert to the possibility of invasive meningococcal disease appeared more likely to make a rapid diagnosis. Because this disease is rare, clinicians, especially younger ones, may have little to no personal experience in diagnosing it. We must, therefore, increase efforts to educate HCPs on all of the potential clinical markers for the disease.

Even in the setting of a known outbreak, clinicians failed to make diagnoses of disease, because of the absence of expected (or anticipated) clinical markers or failure to recognize markers. Situational awareness must be improved among HCPs so that they have invasive meningococcal disease in the differential diagnosis during campus outbreaks. Decision-making tools incorporated into the electronic medical record, along with electronic information flow between public health professionals and clinicians that support these tools, can provide powerful educational messages in real time during an encounter.

Meningococcal disease incidence is well known to be cyclical. If US incidence increases again, our public health and health care systems need to be prepared. This includes making sure younger clinicians know how to recognize, diagnose, and treat cases and report them promptly to public health authorities.

Back to Top | Article Outline
Educational Resources Need to Be Readily Available for the Public When Outbreaks Occur

Educating affected populations about risk reduction and convincing college students to minimize risk may mean an undesirable change in lifestyle to many. Students are unlikely to alter their social behaviors except in cases where their fear is heightened (eg, during an outbreak), so it is essential to reach them as quickly as possible after a case is reported.

It is extremely difficult to deliver definitive messages in the face of such an uncertain disease. An evidence-based social marketing campaign that addresses both vaccination and healthy behaviors can be developed for ready use during outbreaks to help universities provide reassurance and accurate information in a timely manner. These campaigns can also contain materials that can be used proactively before an outbreak occurs.

Back to Top | Article Outline
The FDA Should Communicate Clearly About the New Licensure Pathway for Meningococcal Serogroup B Vaccines

A new “breakthrough therapy” pathway has been established by the FDA, and serogroup B meningococcal vaccines are the first vaccines to be granted review under this new procedure. The FDA should communicate clearly about its process and licensure steps, as well as anticipated timing, so that the concerned public is informed.

In this case, data from geographical locations with much higher incidence of serogroup B disease may prove useful, facilitating rapid FDA assessment of vaccine safety and efficacy.

Back to Top | Article Outline
Media Need to Be Engaged in a Thoughtful and Positive Way by All Stakeholders

Media coverage can heighten public fear and may not always provide accurate and balanced information that communicates what public health officials know and the realities of the US vaccine approval process. Every public health official and infectious disease specialist who has contact with media must increase efforts to help reporters present medically accurate information to the public utilizing risk communication skills. Resources should be dedicated to providing media with easy access to information on all aspects of meningococcal disease diagnosis, treatment, transmission, and prevention to inform future news coverage.

Back to Top | Article Outline
The Capacity for Rapid Identification of Meningococcal Serogroups Must Be Maintained

As invasive meningococcal disease incidence has declined in the United States, it has become cost prohibitive for some local laboratories to maintain their capacity to test isolates. This is particularly problematic in the case of serogroup B outbreaks because serogrouping is the first essential step in determining whether the strain causing the outbreak is covered by available vaccines.

One clinician at a large medical center reports that the change from the ability to serogroup inside the medical center to having to send the isolates out to the city or state health department means a delay of 7 to 10 days in serogroup identification. Even though the incidence of invasive meningococcal disease is low, its severity and ability to cause public panic support the need for public health laboratories to maintain the capacity for rapid serogrouping of meningococcal isolates.

Back to Top | Article Outline
Epidemiologic Definitions of Outbreaks Should Be Reviewed and Updated, as Necessary

The outbreaks at UCSB and Princeton showed that links are not always clear, and yet outbreaks can flourish. Longer intervals between cases, and cases such as the one that occurred in a Princeton student traveling in Greece with classmates, show that this pathogen can be carried asymptomatically in some individuals who can then pass it on to others who may become symptomatic. The characteristics that make some individuals carriers and others victims are not well enough defined to drive our definition of outbreaks. Studies in the United Kingdom have demonstrated widespread acquisition of the carrier state among college students shortly after arrival on campus.23 With widespread acquisition of the carrier state among students, searching for evidence of close connections between cases may not be needed before an outbreak is declared.

The CDC Advisory Committee on Immunization Practices Meningococcal Vaccine Work Group is addressing this challenge by reviewing the nature of the recent outbreaks to determine whether current outbreak definitions need to be adjusted. Outbreak definition adjustments and more flexible definitions of connectivity between cases also could expand the scope of those who should receive postexposure antibiotic prophylaxis.

Back to Top | Article Outline
Consider How Resources Influence When and How Outbreaks Are Declared and Managed

Managing an outbreak is a challenging process for any campus, but it is even more difficult for those with fewer available resources. For instance, campuses without a student health center, such as community colleges, may not be able to respond directly. They will likely rely on the capacity of local public health departments. But this may not be a viable solution in all areas. As the outbreak at UCSB showed, local public health departments also have resource limitations, and meningococcal outbreaks have the capacity to quickly overtake available resources. There is currently no clear schematic to follow that defines roles for universities and the various public health agencies (local, state, CDC) in outbreak declaration and control.

Back to Top | Article Outline
Once an Outbreak Is Declared, Prevention Programs Must Be Implemented as Quickly as Possible

In recent outbreaks, campus and public health officials noted that both student and parent perception of risk was a major factor in participation in prevention measures. The longer the period from the last cases to the availability of the prevention program, the harder it will be to motivate participation. When fear is high, motivation is high.

At UCSB, teammates of a case self-identified and came to the infirmary asking for chemoprophylaxis. At Princeton, where the time from the last case to the first vaccine clinic was very short, vaccination rates exceeded 90% of the targeted 9000 students. At UCSB, where the gap was 3 months between the last case and the first vaccine clinic, the rate was 51% of the targeted 19,000 students. Availability of a licensed vaccine should help to shorten the time between the decision to undertake a vaccination program and the actual implementation.

Back to Top | Article Outline
Universities Should Consider Advanced Planning About Ways to Cover Costs of Managing Outbreaks

Meningococcal outbreaks are extremely rare, but very costly. Universities faced with an outbreak are not likely to have the luxury of deciding whether to incur certain expenses. Nor are they likely to have the time to find the most cost-efficient ways to deal with the outbreak. The cost of vaccine procurement is just a fraction of the total expenses involved in managing an outbreak. Examples of costs unlikely to be covered by any type of insurance include developing and printing materials for education and awareness campaigns; increased communications with parents, the general public, the media, and others; greatly increased need for on-campus counseling—medical and psychological; purchasing refrigerators for vaccine storage and other required equipment; physical setup of clinics, including Internet service and privacy screens; and hiring additional nursing or administrative support personnel for clinic staffing.

Because this is a complicated issue, and it is not possible to plan ahead for every eventuality, universities should examine their insurance policies and consider the feasibility of adding coverage that could help offset some of the costs associated with outbreaks. Declared public health emergencies may also help distribute costs.

Back to Top | Article Outline

SUMMARY

Although rare, invasive meningococcal disease requires public health attention because of its severity. Invasive meningococcal disease is fast moving and causes significant morbidity and mortality. Even 1 case on a college campus can induce a great deal of public anxiety. But it is not only the public that expresses concern and anxiety. Health care professionals worry about their ability to quickly recognize a potential case, confirm the diagnosis, begin treatment, and report it to public health authorities.

The impact on financial and personnel resources begins with just 1 case and expands greatly in the event of an outbreak. College campuses are often not equipped to deal with the repercussions on their own. Defining an outbreak, planning for control, and implementing containment procedures require input and active participation of a range of experts.

Because not every eventuality can be foreseen, advanced planning is essential for invasive meningococcal disease outbreaks, which can strike at any time and have a high likelihood of being severe and causing public panic. It is imperative that we give officials the tools they need when faced with such outbreaks. This includes safe and effective vaccines and antibiotics and clear direction on their use; ongoing education and laboratory capacity (eg, rapid isolate testing) to ensure HCPs can make accurate and quick diagnoses; ready-made public education and awareness materials that can be easily customized; and finally, a roadmap that helps them navigate the difficult path from an isolated case to resolution of an invasive meningococcal disease outbreak.

Back to Top | Article Outline

REFERENCES

1. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013; 62:( RR-2): 1–28.

2. Mandal S, Wu HM, MacNeil JR, et al. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis. 2013; 57:( 3): 344–348.

3. Brooks R, Woods CW, Benjamin DK Jr, et al. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994–2002. Clin Infect Dis. 2006; 43: 49–54.


5. Snape MD, Pollard AJ. The beginning of the end for serogroup B meningococcus? Lancet. 2013; 381:( 9869): 785–787.

6. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13–17 years—United States, 2012. MMWR Morb Mortal Wkly Rep. 2013; 62:( 34): 685–693.

7. http://www.cdc.gov/meningococcal/outbreaks/vaccine-serogroupB.html

Centers for Disease Control and Prevention. Serogroup B meningococcal vaccine and outbreaks (questions and answers). Available at: http://www.cdc.gov/meningococcal/outbreaks/vaccine-serogroupB.html. Accessed April 22, 2014


8. http://www.novartis.com/newsroom/media-releases/en/2014/1774805.shtml

Novartis meningitis B vaccine Bexsero® receives FDA breakthrough therapy designation in the US [news release]. Basel, Switzerland: Novartis; April 7, 2014. Available at: http://www.novartis.com/newsroom/media-releases/en/2014/1774805.shtml. Accessed April 16, 2014


9. http://press.pfizer.com/press-release/pfizers-investigational-vaccine-candidate-bivalent-rlp2086-receives-us-food-and-drug-a

Pfizer’s investigational vaccine candidate bivalent rLP2086 receives U.S. Food and drug administration breakthrough therapy designation for potential prevention of meningococcal B disease [news release]. New York, NY: Pfizer, Inc; March 20, 2014. Available at: http://press.pfizer.com/press-release/pfizers-investigational-vaccine-candidate-bivalent-rlp2086-receives-us-food-and-drug-a. Accessed April 16, 2014



11. Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012; 30:suppl 2: B3–B9.

12. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr. 1981; 99: 540–545.

13. Kirsch EA, Barton P, Kitchen L, Giroir BP. Pathophysiology, treatment, and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J. 1996; 15: 967–979.

14. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria Meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010; 50: 184–191.

15. Froeschle JF. Meningococcal disease in college students. Clin Infect Dis. 1999; 29:( 1): 215–216.

16. Harrison LH, Dwyer DM, Maples CT, et al. Risk of meningococcal infection in college students. JAMA. 1999; 281: 1906–1910.

17. Imrey PB, Jackson LA, Ludwinski PH, et al. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. J Clin Microbiol. 1995; 33:( 12): 3133–3137.

18. Imrey PB, Jackson LA, Ludwinski PH, et al. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol. 1996; 143:( 6): 624–630.

19. Centers for Disease Control and Prevention. Summary of notifiable diseases, 2011: meningococcal disease, invasive. MMWR Morb Mortal Wkly Rep. 2013; 60:( 53): 18

20. http://www.cdc.gov/abcs/reports-findings/surv-reports.html

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) cases from 1993–2012. Available at: http://www.cdc.gov/abcs/reports-findings/surv-reports.html


21. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 2001; 344: 1378–1388.

22. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J Infect Dis. 1999; 180: 1894–1901.

23. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ. 2000; 320:( 7238): 846–849.

Back to Top | Article Outline
Self Assessment Examination

A minimum assessment score of 80% is required.

  1. Which of the following meningococcal serogroups is not included in the quadrivalent meningococcal vaccines licensed in the United States?
    1. A
    2. B
    3. C
    4. W-135
    5. Y
  2. Despite the availability of effective antibiotic therapy, the mortality associated with meningococcal disease is approximately:
    1. 10%–15%
    2. 2%–4%
    3. 30%–40%
    4. 50%–60%
  3. Social behaviors that contribute to the transmission of meningococci among young adults include
    1. smoking.
    2. alcohol consumption.
    3. having more than 1 kissing partner.
    4. frequenting bars and parties.
    5. all of the above.
  4. A striking feature of the epidemiology of meningococcal disease since the 1990s is that its incidence has
    1. increased.
    2. decreased.
    3. remained essentially unchanged.
  5. It has been difficult to create an effective vaccine against serogroup B meningococci because
    1. serogroup B meningococci are rare; thus, it has been difficult to find isolates that are truly representative.
    2. serogroup B meningococci are covered by a thick polysaccharide capsule that shields the underlying membrane proteins from the immune system.
    3. the capsule enveloping group B meningococci chemically resembles similar structures on human cells, so the immune system does not recognize it as foreign.
    4. the proteins of group B meningococci clump when suspended in liquids, thus shielding their active sites from the immune system.
Back to Top | Article Outline
Evaluation

Your input is important in improving future publications and identifying areas of need for other educational activities. Please circle the choice that best answers the following:

  1. The format was appropriate for the subject matter.
    • Agree Neutral Disagree
  2. This activity supported achievement of the learning objectives.
    • Agree Neutral Disagree
  3. The material was organized clearly for learning to occur.
    • Agree Neutral Disagree
  4. I acquired a new strategy to use in my clinical practice.
    • Agree Neutral Disagree
  5. The activity was objective and free of commercial bias.
    • Agree Neutral Disagree
  6. I would recommend this activity to my colleagues.
    • Agree Neutral Disagree
  • 7. I spent _________ minutes participating in this activity.

Additional comments and suggested continuing education topics that would be of value to you:

___________________________________________________

___________________________________________________

You must print legibly and provide all of the information below to obtain credit. Your certificate will be sent to the e-mail address provided.

Name/degree________________________________________

Title_______________________________________________

Affiliation __________________________________________

Address ____________________________________________

City_______________________State___________Zip_______

E-mail _____________________________________________

Telephone __________________________________________

Check the appropriate box:

□ I am an MD or DO and wish to receive 0.5 AMA PRA Category 1 Credits.

□ I wish to receive a certificate of completion.

___________________________ ____________________

Signature Date

Keywords:

meningococcal disease; serogroup B; outbreak; immunization; vaccine; college health

Copyright © 2014 by Lippincott Williams & Wilkins

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.